Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 30:4:PO.19.00359.
doi: 10.1200/PO.19.00359. eCollection 2020.

Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options

Michael Bitzer  1   2   3 , Leonie Ostermann  1 , Marius Horger  4 , Saskia Biskup  5 , Martin Schulze  5 , Kristina Ruhm  3 , Franz Hilke  6 , Öznur Öner  3 , Konstantin Nikolaou  2   4 , Christopher Schroeder  6 , Olaf Riess  6 , Falko Fend  7   8 , Daniel Zips  8   9 , Martina Hinterleitner  10 , Lars Zender  2   8   10 , Ghazaleh Tabatabai  2   8   11 , Janina Beha  3 , Nisar P Malek  1   2   3   8
Affiliations
Review

Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options

Michael Bitzer et al. JCO Precis Oncol. .

Abstract

Purpose: Precision oncology connects highly complex diagnostic procedures with patient histories to identify individualized treatment options in interdisciplinary molecular tumor boards (MTBs). Detailed data on MTB-guided treatments and outcome with a focus on advanced GI cancers have not been reported yet.

Patients and methods: Next-generation sequencing of tumor and normal tissue pairs was performed between April 2016 and February 2018. After identification of relevant molecular alterations, available clinical studies or in-label, off-label, or matched experimental treatment options were recommended. Follow-up data and a response assessment that was based on radiologic imaging were recorded.

Results: Ninety-six patients were presented to the MTB of Tuebingen University Hospital. Sixteen (17%) showed "pathogenic" or "likely pathogenic" germline variants. Recommendations on the basis of molecular alterations or tumor mutational burden were given for 41 patients (43%). Twenty-five received the suggested drug, and 20 were evaluable for best response assessment. Three patients (15%) reached a partial response (PR), and 6 (30%), stable disease (SD), whereas 11 (55%) had tumor progression (progressive disease). Median progression-free survival (PFS) for all treated and evaluable patients was 2.8 months (range, 1.0-9.0 months), and median overall survival (OS) of all treated patients was 5.2 months (range, 0.1 months to not reached). Patients with SD for ≥ 3 months or PR compared with progressive disease showed both a statistically significant longer median PFS (7.8 months [95% CI, 4.2 to 11.4 months] v 2.2 months [95% CI, 1.5 to 2.8 months], P < .0001) and median OS (18.0 months [95% CI, 10.4 to 25.6 months] v 3.8 months [95% CI, 2.3 to 5.4 months], P < .0001).

Conclusion: Next-generation sequencing diagnostics of advanced GI cancers identified a substantial number of pathogenic or likely pathogenic germline variants and unique individual treatment options. Patients with PR or SD in the course of MTB-recommended treatments seemed to benefit with respect to PFS and OS.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Michael BitzerConsulting or Advisory Role: Bristol-Myers Squibb, Bayer Vital GmbH, EISAI, Ipsen, Lilly Travel, Accommodations, Expenses: Ipsen, CelgeneSaskia BiskupEmployment: CeGaT Stock and Other Ownership Interests: CeGaTMartin SchulzeEmployment: Praxis für Humangenetik TuebingenFranz HilkeHonoraria: Agilent Technologies Research Funding: Novartis (Inst) Travel, Accommodations, Expenses: Agilent TechnologiesKonstantin NikolaouHonoraria: Siemens Healthineers, Bayer Schering Pharma Consulting or Advisory Role: Siemens Healthineers Speakers' Bureau: Siemens Healthineers Research Funding: Siemens Healthineers (Inst), Bayer Schering Pharma (Inst) Travel, Accommodations, Expenses: Siemens Healthineers, Bayer Schering PharmaChristopher SchroederResearch Funding: Illumina (Inst), Novartis (Inst)Olaf RiessHonoraria: AstraZeneca, Takeda/Shire Consulting or Advisory Role: Illumina Research Funding: Illumina (Inst)Falko FendConsulting or Advisory Role: Roche, EUSA PharmaDaniel ZipsResearch Funding: Elekta (Inst), Siemens (Inst), Sennewald (Inst) Travel, Accommodations, Expenses: Elekta (Inst)Martina HinterleitnerTravel, Accommodations, Expenses: Novartis/IpsenLars ZenderLeadership: HeparegeniX GmBH Consulting or Advisory Role: Boehringer Ingelheim Research Funding: HeparegeniX GmBH Patents, Royalties, Other Intellectual Property: Patent on MKK4 Inhibition for the treatment of acute and chronic liver diseases Travel, Accommodations, Expenses: IpsenGhazaleh TabatabaiHonoraria: AbbVie, Bayer, Medac, Novocure (Inst) Consulting or Advisory Role: AbbVie, Bayer Travel, Accommodations, Expenses: Novocure (Inst)Nisar P. MalekHonoraria: Spring Bank Travel, Accommodations, Expenses: Falk Foundation No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Next-generation sequencing (NGS) of GI tumors. (A) No. of patients with different tumor types. (B) No. of pretreatments before presentation at the molecular tumor board. (C) Performed diagnostic test. (D) No. of identified pathogenic or likely pathogenic germline variants per tumor type. (E) Genes that show pathogenic germline variants. (F) Genes that show likely pathogenic germline variants. BTC, biliary tract cancer; CRC, colorectal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; NET, neuroendocrine tumor; PC, pancreatic cancer; UGC, upper GI tract cancer.
FIG 2.
FIG 2.
Course of patients after initiating next-generation sequencing (NGS). (A) Frequency of clinically relevant germline variants. (B) Molecular target identification and course of patients. MTB, molecular tumor board; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease
FIG 3.
FIG 3.
Tumor mutational burden and target identification per tumor type. (A) Tumor mutational burden was calculated for 88 patients. Two patients had 3, and 3 patients had 2, different calculations of separate tissue samples over the observation period, which are included in the analysis. The median is shown for each tumor type. (B) Frequency of potential target identification by the molecular tumor board (MTB), patients with target identification but no treatment, and patients with MTB-recommended treatment initiation. (C) Frequency of target identification per tumor type. BTC, biliary tract cancer; CRC, colorectal cancer; HCC, hepatocellular carcinoma; NET, neuroendocrine tumor; PC, pancreatic cancer; UGC, upper GI tract cancer; w/o, without.
FIG 4.
FIG 4.
Outcomes of patients treated according to molecular tumor board (MTB) recommendations. (A) Progression-free survival (PFS), defined as the time from start of an MTB-recommended treatment to radiographic progression or death, and (B) overall survival (OS), defined as the time from start of an MTB-recommended treatment to death as a result of any cause, in days. Shown are individual patient identifiers and treatments. (*) Patients who were treated according to identified germline alterations. Kaplan-Meier analysis of (C) PFS and (D) OS in evaluable patients according to best response. The estimation compared patients who reached a partial response (PR) or stable disease (SD) with patients with progressive disease (PD). Tick marks indicate censored data. BTC, biliary tract cancer; CRC, colorectal cancer; HCC, hepatocellular carcinoma; PC, pancreatic cancer; UGC, upper GI cancer.
See this image and copyright information in PMC

References

    1. Hoefflin R, Geißler A-L, Fritsch R, et al. Personalized clinical decision making through implementation of a molecular tumor board: A German single-center experience. JCO Precision Oncol. 2018 10.1200/PO.18.00105. - DOI - PMC - PubMed
    1. Meric-Bernstam F, Brusco L, Shaw K, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol. 2015;33:2753–2762. - PMC - PubMed
    1. Bryce AH, Egan JB, Borad MJ, et al. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget. 2017;8:27145–27154. - PMC - PubMed
    1. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–713. Erratum: Nat Med, 2017. - PMC - PubMed
    1. Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015;7:283ra53. - PMC - PubMed